Personalis (PSNL) to Release Earnings on Tuesday

Personalis (NASDAQ:PSNL) will likely be posting its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect Personalis to post earnings of ($0.28) per share and revenue of $13.3070 million for the quarter. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 4, 2025 at 5:00 PM ET.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.02. The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $20.12 million. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%. On average, analysts expect Personalis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Personalis Trading Up 1.4%

PSNL opened at $9.64 on Monday. The firm has a market cap of $854.88 million, a price-to-earnings ratio of -7.53 and a beta of 1.92. Personalis has a 12 month low of $2.83 and a 12 month high of $10.95. The stock has a fifty day moving average price of $7.02 and a 200-day moving average price of $5.93.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $8.50 price target on shares of Personalis in a research report on Monday, September 8th. Finally, BTIG Research boosted their price target on Personalis from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.25.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PSNL. Legal & General Group Plc acquired a new position in Personalis during the 2nd quarter valued at about $30,000. BNP Paribas Financial Markets increased its holdings in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares during the period. Focus Partners Wealth acquired a new position in shares of Personalis in the first quarter valued at about $47,000. New York State Common Retirement Fund acquired a new position in shares of Personalis in the second quarter valued at about $104,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Personalis in the second quarter valued at about $123,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.